Skip to main content
. 2021 Aug 17;18(4):992–1009. doi: 10.20892/j.issn.2095-3941.2020.0806

Figure 2.

Figure 2

Combinations of MDSC-targeted compounds and ICB. A. SX-682, the Sema4D mAb and VPA inhibit the MDSC recruitment pathway; B. HDC promotes the MDSC differentiation pathway; C. The TRAILR2 agonistic antibody promotes the MDSC elimination pathway; D. Phenformin and DMBG inhibit the L-arginine elimination pathway mediated by MDSCs; E. Indoximod, epacadostat, and navoximod inhibit the IDO pathway in MDSCs; F. Entinostat and inhibitors of PI3Kδ and γ inhibit the ROS and RNS pathways in MDSCs.